Medical device company Inari Medical has launched two new purpose-built thrombectomy catheters to address the needs of venous stent thrombosis and venous thromboembolism (VTE).

The two products are the Triever16 Curve catheter and the RevCore thrombectomy catheter.

Part of the FlowTriever platform, the Triever16 Curve catheter is designed for use in both peripheral thrombectomy and pulmonary embolism procedures.

Triever16 Curve is a highly trackable catheter equipped with a pre-shaped curve for targeted aspiration and it further provides distinct benefits compared to 16F continuous aspiration catheters.

The advantages include its compatibility with the FlowSaver blood return system and convenient accessibility to larger and more potent 20F or 24F catheters.

On the other hand, RevCore is claimed to be the first mechanical thrombectomy device developed to treat venous in-stent thrombosis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device comes with an advanced diameter-controlled coring element specially created to safely engage thrombus within stents.

Through the RevCore product, Inari can obtain access to new patients who are not currently treated by the FlowTriever or ClotTriever platforms.

Inari CEO Drew Hykes said: “We are thrilled to announce the commercial launch of these two products, which reinforce our unwavering commitment to addressing unmet needs with purpose-driven innovation.

“We continue to push the boundaries, and we are excited about the potential impact we can make on patients’ lives with these products and beyond.”

Last month, Inari announced planned recruitment for its third randomised controlled trial (RCT) in VTE to assess its FlowTriever system.

PEERLESS II is a multi-centre, prospective, global RCT designed to compare the clinical outcomes of the FlowTriever system against anticoagulation alone in intermediate-risk pulmonary embolism patients.